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The lymphocyte crossmatch is currently the only cell-based compatibility assay
performed by histocompatibility laboratories for transplant purposes. While in
many transplant programs the complement-dependent cytotoxicity crossmatch
(CDCXM) remains in use, when available, the flow cytometry crossmatch
(FCXM) is the method of choice because of its superior sensitivity and specificity.
Unfortunately, the maintenance and cost of a flow cytometer is a considerable limi-
tation for small histocompatibility laboratories. Therefore, in this study, we evalu-
ated the use of the Cellometer Vision CBA image cytometer (Nexcelom
Bioscience LLC, Lawrence, Massachusetts) as an alternative instrument to perform
the crossmatch assay. The 3-color FCXM protocol was modified into two separate
2-color panel image cytometry crossmatches (IXMs), one for T cells and one for B
cells. After initial serum and cell incubation, a cocktail consisting of
PE/Cy5-conjugated anti-human CD3 or CD19 and PE-conjugated anti-human IgG
F(ab0)2 was added to the T cell and B cell panels, respectively. The final cell prepa-
ration was added to a separate counting chamber. Images were captured using the
Cellometer Vision CBA, an image cytometer designed for cell counting, size analy-
sis and fluorescence intensity measurement. Thirty-nine IXMs were performed and
compared with the FCXM. We obtained a concordance sensitivity of 94.1% and
100% and specificity of 100% and 88.9% for T cells and B cells, respectively. The
linearity of the system was verified using dilutions of a sample containing known
donor-specific anti-HLA antibodies (DSA) against the target cells. This feasibility
study demonstrates that the FCXM test could be easily adapted to the Cellometer
Vision CBA image cytometer without compromising specificity and sensitivity.
The low instrumentation cost, minimal maintenance, and simple operation allow
for efficient implementation or transition from the FCXM to the IXM method.
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1 | INTRODUCTION
Organ transplantation is a well-established treatment for pro-
gressive and irreversible organ failure. Two large immuno-
logic barriers must be overcome before most solid organ
transplant procedures. The first is the compatibility of ABO
blood groups, and the second is the presence of preformed
anti-HLA antibodies in the serum of the organ recipient. The
crossmatch reaction has been an essential tool to facilitate
organ distribution, donor selection, and post-transplant risk
assessment. With the original complement-dependent cyto-
toxicity crossmatch (CDCXM) reaction, a positive result
Received: 30 January 2019 Revised: 27 February 2019 Accepted: 1 March 2019
DOI: 10.1111/tan.13515
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
436 wileyonlinelibrary.com/journal/tan HLA. 2019;93:436–444.
was associated with hyperacute or accelerated rejection, pro-
duced by massive complement cascade activation due to the
high concentration of donor-specific anti-HLA antibodies
(DSA) demonstrated by the pivotal work of Patel and
Terasaki.1
The low sensitivity to detect DSA was the main limita-
tion of the CDCXM. This assay was later modified to
improve its sensitivity and specificity with the addition of
washing steps or incubation with anti-human globulin
(AHG)2,3 without substantial changes in the performance
characteristics of the assay. Despite these limitations, the
CDCXM remains in use in many laboratories around the
world and it is a requirement for transplantation in many
programs.
A considerable improvement in sensitivity and specific-
ity was achieved with the introduction of the flow cyto-
metry crossmatch (FCXM).4 This and other studies showed
that the FCXM was capable of detecting low DSA levels
not previously detected by the CDCXM.5–8 Most notably,
renal transplant recipients exhibiting negative CDCXM or
AHG-augmented CDCXM, but positive FCXM, were more
likely to experience early accelerated rejection and graft
loss.9–12 Hence, for the assessment of alloantibody reactiv-
ity, in those laboratories with access to a flow cytometer,
the FCXM replaced the CDCXM as the pre-transplant
crossmatch assay.
Simultaneously, new solid-phase methods became avail-
able to the histocompatibility laboratory for the detection
and characterization of anti-HLA antibodies, allowing for a
crossmatch prediction algorithm known as the virtual
crossmatch (VXM).13 However, despite the reliability of the
VXM, many transplant centers, combined the information
from solid-phase methods and the FCXM for the final trans-
plant decision and risk assessment.
Without a doubt, the flow cytometer is an excellent
instrument to perform the FCXM assay. Among the bene-
fits that can be highlighted are the high sensitivity and
specificity, the simultaneous detection of multiple analytes,
and the more than 30 years of experience of clinical appli-
cation. This instrument is constructed with multiple lasers
to excite a large number of fluorescent labels and a sophis-
ticated optical system to collect and filter the emission fluo-
rescent light, as well as to analyze the size and internal
complexity of a large number of particles. Furthermore, the
instrument is designed with an intricate pneumatic and flu-
idic system; thus, the acquisition cost of this instrument is
relatively high. In addition, the complex setting and opera-
tion of the flow cytometer, as well as laborious mainte-
nance, can make training difficult and requires a
considerable amount of time.
Substantial technological advances in the acquisition of
digital images, microfluidics and compact light-emitting
diodes (LEDs) as a source of fluorochrome excitation light
have allowed the development of a simple and compact type
of instrument capable of reproducing some of the functions
performed using the flow cytometer. The replacements of
expensive and bulky lasers and the complex fluidic systems
by compact and affordable LED bulbs and microfluidic
chambers have given rise to small footprint benchtop instru-
ments with lower acquisition costs and virtually no mainte-
nance cost. With this currently available technology, the
crucial concern is whether the flow cytometer remains the
most adequate instrument for a relatively simple detection
like the crossmatch assay.
In this study, we explored the possibility of employing
an image cytometer instrument, the Cellometer Vision CBA
(Nexcelom Bioscience LLC), as an alternative instrument to
perform the crossmatch assay. We adapted our FCXM proto-
col to determine whether the crossmatch assay could be ana-
lyzed and interpreted by the image cytometer. As a result,
we validated the performance of the image cytometry
crossmatch (IXM) protocol by comparing the results with
the FCXM results as the reference methodology.
2 | MATERIALS AND METHODS
2.1 | Three-color FCXM
Our laboratory used a 3-color FCXM procedure described
previously.6 Briefly, 5 × 105 lymphocytes were suspended
in wash buffer (5% fetal bovine serum and 0.1% sodium
azide in PBS) and then centrifuged at 3000 g in a 12 × 75
polystyrene tube. Forty microliters of the appropriate sam-
ple (NHS [normal human serum], PHS [positive human
serum], and test sera), previously centrifuged at 14000 g,
was added to the cells and incubated at room temperature
for 30 minutes. Subsequently, the cells were washed
3 times with wash buffer. After decanting the wash buffer,
20 μL of FITC-conjugated F(ab’)2 goat anti-human IgG
(Fc-specific) polyclonal antibody (Jackson Immuno-
Research Laboratories, Inc, West Grove, Pennsylvania;
Cat. No. 109-096-098) and 30 μL of a mix of
PE/Cy5-conjugated mouse anti-human CD3 and PE-
conjugated mouse anti-human CD19 monoclonal anti-
bodies (mAb) (Beckman Coulter, Inc., Brea, California;
Cat. No. IM2635/IM1285) were added to each tube and
incubated at room temperature for 20 minutes in the dark.
Next, the cells were washed twice with wash buffer and
resuspended. The FCXM was analyzed in an FC500
Beckman Coulter flow cytometer (Beckman Coulter, Inc.).
Forward vs side scatter and CD3 vs CD19 dot plots were
used to analyze T cell and B cell populations individually.
From a histogram with the cell count and the FITC signal
intensity, the median channel (MC) for each sample was
determined. Fluorescence median channel shift (MCS)
was calculated by subtracting the NHS fluorescence MC
value from the PHS and test sera fluorescence MC values.
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The MCS values were compared to the previously calcu-
lated cut-off value for positive or negative assignment.7,14
2.2 | Image cytometry instrumentation and disposable
counting chamber
The Cellometer Vision CBA image cytometer (Nexcelom
Bioscience, LLC) has been described previously.15–17 The
system utilized bright-field (BR) and dual-fluorescent (FL1
and FL2) imaging modes to quantitatively analyze and mea-
sure the fluorescence intensities of target cells. BR imaging
used a white LED, and fluorescent imaging used a combina-
tion of monochromatic LEDs (527 and 624 nm) as excita-
tion light sources. The monochromatic LEDs were
integrated into specific fluorescence optics modules
(excitation/emission), VB-595-502 (525 ± 32/605 ± 22 nm)
for PE and VB-695-502 (525 ± 32/695 ± 30 nm) for PE/
Cy5 detection. The system uses a magnification objective of
5× and the optical detection limit has been previously
described.15 Typically, the fluorescently labeled cell sample
is pipetted into a Nexcelom disposable counting chamber,
which holds precisely 20 μL of volume. The counting slide
is held in position by a stage, which automatically moves to
four locations on the chamber for cellular analysis by the
Cellometer Vision CBA instrument's software. The software
analyzes three image channels (BR, FL1, and FL2) and gen-
erates a fluorescent dataset that is automatically exported to
FCS Express 4 image cytometry software (De Novo Soft-
ware, Los Angeles, California).
2.3 | Two-color image cytometry crossmatch
The 3-color FCXM panel was adapted to two separate
2-color T cell and B cell panels, respectively. For the T cell
panel we used PE/Cy5-conjugated mouse anti-human CD3
mAb (Immunotech, Beckman Coulter; Cat. No. IM2635U)
and PE-conjugated F(ab’)2 goat anti-human IgG (Fc-spe-
cific) polyclonal antibody (Jackson ImmunoResearch Labo-
ratories, Inc.; Cat. No. 109-116-098). The only difference on
the B cell panel was the replacement of the PE/Cy5
-conjugated mouse anti-human CD3 mAb by the PE/Cy5
-conjugated mouse anti-human CD19 mAb (Immunotech,
Beckman Coulter; Cat. No. IM2643U). Besides the changes
in the mAbs, the rest of the crossmatch reactions remained
consistent with the FCXM protocol. Parameters such as cell
number, incubation time, and concentration and volume of
reagents were maintained. After the suspension of the cells
with wash buffer, 20 μL of each reaction was dispensed into
each side of the Nexcelom disposable counting chamber
(Figure 1).
Four sets of BR, FL1, and FL2 fluorescent images were
collected from each chamber containing the NHS, PHS, and
test serum crossmatch reactions. The images were seg-
mented and exported as .NXDAT files to be analyzed by the
FCS Express 4 image cytometry software (Figure 2).
2.4 | Parallel study
2.4.1 | Cell preparation
The contents of 3 to 4 ACD blood collection tubes
(20-25 mL) were transferred into a 50-mL conical tube.
Forty μL of RosetteSep (Stemcell Technologies Inc., Van-
couver, BC, Canada) were added, and the sample was
vortexed gently and then incubated for 10 minutes at room
temperature. The sample was overlaid onto the Ficoll-
Hypaque chamber in the SepMate tube (Stemcell Technolo-
gies, Inc.). After centrifugation at 1200 g for 20 minutes, the
upper supernatant was transferred into a 50-mL conical tube.
Next, the tubes were centrifuged at 1200 g for 5 minutes,
where the cell pellet was washed twice with RPMI-1640
medium and resuspended in 2 mL of wash buffer. Subse-
quently, the cells were counted with the volume adjusted to
a concentration of 5 × 106 cells/mL. Next, the tubes were
centrifuged at 1200 g for 5 minutes. After removal of the
supernatant, 1 mL of pronase solution (2.8 units pro-
tease/mL) was added and the cells were incubated at 37C
for 10 minutes. Finally, the cells were washed with RPMI-
1640 medium supplemented with 10% fetal bovine serum
and washed twice with wash buffer with the concentration
adjusted to 2.5 × 106 cells/mL. All samples were typed by
SSO method (LABType, One Lambda, Inc., Canoga Park,
California) for HLA-A, B, C, DRB1, DRB3/4/5, DQA1, and
DQB1, and for HLA-DPA1 and DPB1 in cases with anti-
bodies against HLA-DP molecules.
2.5 | Serum samples
Thirty-nine patient sera were tested in this study. The detec-
tion and characterization of anti-HLA antibodies was per-
formed utilizing a Luminex single antigen bead (SAB) array
(LABScreen, One Lambda, Inc.) following the manufacturer
instructions. The product of this reaction was analyzed by
the Luminex LABScan 200 flow analyzer (Luminex Corpo-
ration, Austin, Texas), where the raw data was collected and
analyzed by Fusion software (One Lambda, Inc.). The
strength of anti-HLA antibodies was expressed as mean fluo-
rescence intensity (MFI) units.
Commercially available pooled serum from healthy AB
donors (Gemini Bio-Products, West Sacramento, California;
Cat. No. NC9833877) was used as negative control (NHS).
The positive control (PHS) was obtained by pooling sera
from multiple highly sensitized patients (PRA ≥ 80%) with
confirmed antibodies against both HLA class I and class II
antigens by Luminex SAB array.
2.6 | Statistical analysis
Differences in IXM and FCXM reactivity were analyzed by
means of linear regression and Fisher exact tests using Gra-
phPad Prism version 6.07 for Windows (GraphPad Software,
Inc., La Jolla, California) with the alpha set at P < 0.01.
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3 | RESULTS
3.1 | Identification/phenotyping of T cell and B cell
populations
The cell preparation with the initial negative selection and
subsequent separation of mononuclear cells with density gra-
dient centrifugation yielded a highly purified lymphocyte
population. The Cellometer software scanned the BR image
acquired by the image cytometer and searched for dark
membranes of the cells for enumerations. Figure 2A,B show
a pure and uniform cell size distribution. The fluorescence
optic module VB-595-502 (525 ± 32/605 ± 22 nm) col-
lected the emission light from the PE-conjugated anti-human
IgG F(ab0)2 (Figure 2C) and the fluorescence optic module
VB-695-502 (525 ± 32/695 ± 30 nm) collected the emis-
sion light from the PE/Cy5-conjugated anti-CD3 or anti-
CD19 mAbs to detect T cells or B cells, respectively
(Figure 2D). The fluorescent image segmentations were
exported to the FCS Express 4 image cytometry software,
where scatter plots were generated using the PE-conjugated
anti-IgG F(ab0)2 and PE/Cy5-conjugated anti-CD3/CD19
fluorescent signals for each sample (Figure 2E).
The percentage of events collected from the scatter plot
quadrants 1 and 2 on Figures 3A and 4B representing the T
cell population show an average of 71%, while the percent-
age of events collected from the same quadrants (1 and 2) on
Figures 3B and 5B representing the B cell population show
an average of 20%. These percentages of T cells and B cells
are within the range of the normal values demonstrated by
flow cytometry on mononuclear cells from healthy sub-
jects.18 The overlay analysis of the CD3 and CD19 antigen
expression from multiple cells demonstrates that the system
is capable of identifying uniform T cell and B cell
populations as shown in Figure 3C,D, respectively.
3.2 | Serum titration analysis/linear correlation
Subsequently, a titration study was performed to evaluate
the specificity of the fluorescence signals obtained in the
anti-IgG F(ab0)2-PE channel. A serum sample containing a
well-defined DSA profile against the selected target cells
was tested at different dilutions (1:1, 1:2, and 1:8) (Figures 4
and 5).
Figures 4A and 5A (T cells and B cells, respectively)
show that the intensity of the events captured on the digital
image by the PE modules (VB-595-502 [525 ± 32/605 ±
22 nm]) is proportional to the DSA concentration in the
sample at different dilutions. The intensity of the events on
the PE and PE/Cy5 channels are presented in scatter plots
comparable to the flow cytometer analysis (Figures 4B and
5B for T cells and B cells, respectively). The shift in the
anti-IgG F(ab0)2-PE channel can be also collected in an
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FIGURE 1 Two-color image cytometry crossmatch protocol. The 2-color T cell and B cell image cytometry crossmatch (IXM) protocol was adapted from
the 3-color flow cytometry crossmatch (FCXM) protocol. Besides the reduction in fluorochromes, the rest of the reactions remained consistent with the
FCXM protocol
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overlay graph for easy comparison with the negative control
(Figures 4C and 5C for T cells and B cells, respectively)
Similar serum dilutions/target cell combinations (1:1,
1:2, 1:4, and 1:8) were also tested in parallel with the
3-color FCXM protocol to compare the linearity of the fluo-
rescent signal in both instruments. The fluorescence median
value on the PE channel from the Cellometer and the fluo-
rescence median value on the FITC channel from the flow
cytometer were transformed into the 256 linear MC for each
dilution. The MCS for T cells and B cells crossmatching
with each dilution using the FCXM and IXM protocols were
analyzed using linear regression. As shown in Figure 6A,B,
there was a significant correlation (R2 = 0.9986 and 0.9890,
P < 0.01) between both systems for T cell and B cell
crossmatches, respectively.
3.3 | FCXM vs IXM parallel study
Using the 3-color FCXM as the reference method,
39 crossmatches were compared with the T cell and B cell
2-color IXM. We observed one discrepant result for the T cell
crossmatch. The FCXM was positive and the IXM was
negative (Table 1), while the formulated VXM was negative in
concordance with the IXM due to the absence of detectable
DSA against the target cells. On the B cell comparison we
observed two discrepant results. Both discrepant results were
negative by FCXM and positive by IXM (Table 1). One sam-
ple showed DSA against HLA-DR13 (MFI: 5386), and the
other sample showed DSA against HLA-Cw7 (MFI: 5386) and
HLA-DQ7 (MFI: 5899). Of note, in this last sample the T cell
crossmatch results for this serum/cell combination were posi-
tive with both the FCXM and the IXM protocols. The predicted
positive VXM for both samples were in concordance with the
IXM due to the presence of detectable DSA by SAB screening
methods. Table 1 summarizes the results of the parallel study,
with an overall concordance of 96%, and highly significant sen-
sitivity (94.1% and 100%) and specificity (100% and 88.9%)
for T cells and B cells, respectively (P < 0.0001).
4 | DISCUSSION
In this study, we investigated whether the crossmatch assay
can be analyzed and interpreted by the Cellometer Vision
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FIGURE 2 Image collection and analysis. Bright field (A), FL1 (C), and FL2 (D) images were from each chamber. The images were segmented and
exported to be analyzed by FCS Express 4 image cytometry software. FL1 and FL2 indicate dual-fluorescent
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represented in an overlay graph for easy comparison with the negative control (NHS). NHS, normal human serum
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CBA image cytometer. The results from the IXM show a
96% overall concordance when compared with the reference
FCXM method. The results from this proof of concept study
demonstrate that the adapted 2-color IXM protocol from our
3-color FCXM protocol could be successfully analyzed and
interpreted using the image cytometer.
The results generated from the fluorescent images cap-
tured by the image cytometer and the subsequent analysis of
these images, using the FCS Express 4 image cytometry soft-
ware, allowed the correct characterization of the T cell and B
cell populations at the expected proportions of healthy sub-
jects. The correct identification of the target T cells or B cells
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different dilutions. B, Comparable to flow cytometer analysis, the intensity of the events is presented in scatter plots. C, The cell population shift is
represented in an overlay graph for easy comparison with the negative control (NHS). NHS, normal human serum
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is the first step in specificity identification of anti-HLA class I
or class II antibodies; later this information will be correlated
with the detection of DSA on the SAB solid-phase assay.
The titration experiment with a sample containing known
DSA against both HLA class I and class II molecules proves
that the system is capable of detecting different concentrations
of DSA reacting with T cells and B cells. An excellent linear
correlation was obtained when the IXM fluorescent values for
each dilution were compared with the results obtained with
the FCXM (Figure 6). These results demonstrate that the line-
arity and sensitivity are comparable for both instruments.
The parallel study of 39 crossmatches by IXM using the
FCXM as the reference method showed excellent sensitivity
and specificity (Table 1). Three discrepant results were
observed, one for T cell crossmatch and two for B cell
crossmatches. In all these cases, the IXM showed a better
correlation with VXM due to the absence or presence of
DSA on the SAB assay.
The main limitation of our study is the small number of
tested samples; a proper validation will require a larger num-
ber of serum and cells samples to adequately survey the
extensive polymorphism and expression variation of the
HLA system and in the anti-HLA antibodies present in the
serum of sensitized patients. Additionally, the protocol will
need to be performed in multiple laboratories to demonstrate
the robustness and reproducibility of this protocol. Another
limitation of this study is the lack of correlation with trans-
plant outcome; however, the clinical utility of optical alloan-
tibody detection using immunofluorescent techniques was
previously described.19 Using an indirect immunofluores-
cence crossmatch examined by a phase-contrast fluorescence
microscopy, Lobo et al19 showed a significantly higher sen-
sitivity than the CDCXM and a better clinical correlation
with accelerated rejection. These results, together with those
obtained here in the parallel study with the FCXM, allow us
to estimate that the IXM would have a comparable clinical
utility to the FCXM, thus giving it the potential to be used in
the clinical setting for organ distribution, donor selection,
and post-transplant risk assessment.
The utilization of the image cytometry method offers the
advantages of automated and objective data collection for
reliable analyses of the crossmatch samples without possible
variation by different operators. In addition, a larger number
of cells are surveyed, and the data is immediately analyzed
by the FCS Express 4 image cytometry software.
In addition to the concordance between the IXM and the
FCXM results, the image cytometry method has several
technical advantages over conventional flow cytometry. One
major improvement was the ability to analyze CD3/CD19
expression and IgG binding simultaneously on the T cell and
B cell populations, generating the same data plot with the
FCS Express 4 image cytometry software as flow cytometry.
Using PE and PE/Cy5 fluorescent labels without emission
spectral overlapping, fluorescent images for both channels
were generated without optical crosstalk and filter set opti-
mization. Furthermore, the lack of high-power lasers or
photo-multiplying tubes in the image cytometer eliminates
the need for precise optical alignment, where the simple epi-
fluorescence setup does not require daily user maintenance.
Finally, because of the simplicity of the optical architec-
ture, the Cellometer Vision CBA image cytometer does not
have a complex fluidic system to calibrate or maintain.
Bench-top flow cytometers can be cost efficient, but still have
the chance of clogging, risking the sample integrity or signifi-
cantly delaying the results if no backup is available. Because
of the absence of a fluidic system to prime, there is less sam-
ple requirement. While most of the FCXM protocols need
200 to 500 μL, only 20 μL of sample is required using the
image cytometry method. The acquisition of a flow cytometer
is the insurmountable limitation for many laboratories with
limited budget. Typically, a standard flow cytometer requires
an investment over US$100 000, where annual maintenance
fees cost approximately 10% of the instrument. This new gen-
eration of image cytometer instruments typically costs less
than US$30 000 with no required maintenance fees.
In conclusion, the results presented herein validated the
capability and reliability of the Cellometer Vision CBA
image cytometer as a dependable alternative instrument for
the crossmatch assay. The easy operation without the addi-
tional cost and effort of the daily calibration, in addition to
the low acquisition cost, make this instrument an excellent
alternative for histocompatibility laboratories.
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TABLE 1 Performance characteristics of IXM compared to FCXM
T cell (n = 39) B cell (n = 39)
IXM IXM
Positive Negative Positive Negative
FCXM
Positive 16 1 21 0
Negative 0 22 2 16
Sensitivity (95% CI) 94.1% (71.3%-99.9%) 100% (83.9%-100%)
Specificity (95% CI) 100% (84.6%-100%) 88.9% (65.3%-98.6%)
PPV (95% CI) 100% (79.4%-100%) 91.3% (72.0%-98.9%)
NPV (95% CI) 95.7% (78.1%-99.9%) 100% (79.4%-100%)
P-value <0.001 <0.001
Abbreviations: CI, confidence interval, FCXM, flow cytometry crossmatch;
IXM, image cytometry crossmatch; NPV, negative predictive value; PPV, posi-
tive predictive value.
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